Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) had its price objective lifted by Citigroup from $31.00 to $38.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. Citigroup’s price target indicates a potential upside of 9.86% from the stock’s previous close. Several […]